BRAF Alteration in Central and Peripheral Nervous System Tumors
K Srinivasa, KA Cross, S Dahiya - Frontiers in Oncology, 2020 - frontiersin.org
… observed in numerous primary central nervous system tumors as … -BRAF treated with an
analog of vemurafenib exhibit … cases of dramatic and sometimes-sustained response to BRAFi …
analog of vemurafenib exhibit … cases of dramatic and sometimes-sustained response to BRAFi …
Real-world experience with targeted therapy in patients with histiocytic neoplasms in the Netherlands and in Belgium
…, C van den Bos, AGS van Halteren, H Histiocytic… - Blood Neoplasia, 2024 - Elsevier
… the diagnoses of histiocytic sarcoma (HS), Langerhans cell sarcoma 192 and interdigitating
dendritic cell sarcoma, … We also thank Roche for providing vemurafenib and/or cobimetinib. …
dendritic cell sarcoma, … We also thank Roche for providing vemurafenib and/or cobimetinib. …
A rare case of primary central nervous system histiocytic sarcoma harboring a novel ARHGAP45::BRAF fusion: a case report and literature review
L Zhang, G Zhang, H Zheng, B Jiang, Y Ju, Q Duan… - Brain Tumor …, 2024 - Springer
… published cases of primary central nervous system histiocytic sarcoma (PCNSHS) … It has
been demonstrated that vemurafenib treatment resulted in a 3-month response in a BRAF p.…
been demonstrated that vemurafenib treatment resulted in a 3-month response in a BRAF p.…
Histiocytic tumours of the central
O Abla, J Picarsic - Oxford Textbook of Neurohaematology, 2024 - books.google.com
… response to the BRAF-V600E inhibitor vemurafenib was reported in a refractory case of
BRAF-V600E-mutated primary CNS-… for histiocytic sarcoma of the central nervous system. Leuk …
BRAF-V600E-mutated primary CNS-… for histiocytic sarcoma of the central nervous system. Leuk …
Histiocytic Tumors of the CNS
CR Lacruz, E Leonardo - Central Nervous System Tumors: Diagnostic …, 2024 - Springer
… Histiocytic sarcoma (HS) is a malignant hematopoietic … On imaging, HS mimics a malignant
primary CNS tumor, with … V600E mutations may respond to inhibitors (eg, vemurafenib)…
primary CNS tumor, with … V600E mutations may respond to inhibitors (eg, vemurafenib)…
A case of primary histiocytic sarcoma of the central nervous system
R Uno, M Kanzawa, K Tanaka, T Sasayama… - Human Pathology …, 2022 - Elsevier
… Histiocytic sarcoma (HS) is a highly malignant hematopoietic neoplasm that rarely arises in
the central nervous system (CNS)… Histiocytic sarcoma (HS) is a rare malignant hematopoietic …
the central nervous system (CNS)… Histiocytic sarcoma (HS) is a rare malignant hematopoietic …
Treatment of Langerhans cell histiocytosis and histiocytic disorders: a focus on MAPK pathway inhibitors
AV Geerlinks, O Abla - Pediatric Drugs, 2023 - Springer
… responses to a BRAF-V600E inhibitor, vemurafenib, have been shown in a refractory
BRAF-V600E-mutated primary CNS … of disseminated or CNS histiocytic sarcoma remains very …
BRAF-V600E-mutated primary CNS … of disseminated or CNS histiocytic sarcoma remains very …
Histiocytic sarcoma following combination chemotherapy for primary mediastinal germ cell tumor: a diagnostic dilemma
H Yaegashi, Y Kato, T Nohara, K Izumi… - International Cancer …, 2021 - Springer
… staining of BRAF V600E was negative in the … the BRAF inhibitor, vemurafenib, for histiocytic
sarcoma has been reported [11, 12]. A recent phase II study evaluating vemurafenib in BRAF …
sarcoma has been reported [11, 12]. A recent phase II study evaluating vemurafenib in BRAF …
Targeted Therapy for BRAF Mutant Brain Tumors
A Rayi, I Alnahhas, S Ong, P Giglio… - Current treatment options …, 2021 - Springer
… a dramatic impact on several cancers. One such target is … with MEK inhibitors in patients
with BRAF V600E-mutated tumors. FDA-… Patients received vemurafenib 960 mg twice per day …
with BRAF V600E-mutated tumors. FDA-… Patients received vemurafenib 960 mg twice per day …
[HTML][HTML] Rapid but nondurable response of a BRAF exon 15 double-mutated spindle cell sarcoma to a combination of BRAF and MEK inhibitors
K Sinichenkova, I Sidorov, N Kriventsova… - Oncotarget, 2024 - ncbi.nlm.nih.gov
… cells, but contained cell-free tumor DNA BRAF V600E-mutated (VAF = 47%) as measured by
… , the majority of patients develop resistance to vemurafenib + cobimetinib and dabrafenib + …
… , the majority of patients develop resistance to vemurafenib + cobimetinib and dabrafenib + …